Results 81 to 90 of about 811,174 (190)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System

open access: yesJournal of Inflammation Research, 2022
Tingyu Cao,1 Zengguang Wang,2 Xiaodong Zhu1 1Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 2Department of Neurosurgery, Tianjin Neurological Institute, Tianjin ...
Cao T, Wang Z, Zhu X
doaj  

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

open access: yes, 2016
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clinical efficacy in a range of B-cell malignancies. However, acquired resistance has emerged, and second generation therapies are now being sought.
Luciana Burton (3105537)   +21 more
core   +1 more source

Management of chronic urticaria: Current status and future prospect

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman   +15 more
wiley   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

Supplementary data, Figure 1 from Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells

open access: yes, 2016
Structures of BTK inhibitors. Ibrutinib and AVL-292 are irreversible inhibitors, covalently binding to Cys481 of BTK.
Xianhui Wang (153325)   +6 more
core   +1 more source

Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

open access: yesAdvances in Rheumatology
Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase, plays a remarkable role in the transmission and amplification of extracellular signals to intracellular signaling pathways.
Gita Manzari Tavakoli   +2 more
doaj   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

open access: yesTransplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford   +32 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

open access: yesMedComm
Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that couples B‐cell receptor (BCR) signaling to broader immune‐cell activation. By integrating signals from BCR, Toll‐like receptors, chemokine receptors, Fc receptors, and BAFF receptors ...
Miao Sun, Dengju Li, Jia Wei
doaj   +1 more source

Second-generation inhibitors of Bruton tyrosine kinase

open access: yesJournal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu   +3 more
doaj   +1 more source

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin   +92 more
wiley   +1 more source

Home - About - Disclaimer - Privacy